text: Mallinckrodt Joins The Partnership at Drugfree.org to Launch The Medicine Abuse Project | FiercePharma
  Sep 26, 2012 12:02am
  <0> CovidienLynn Phillips, 314-654-3263Manager, Media RelationsPharmaceuticalsorColeman Lannum, CFA, 508-452-4343Vice PresidentInvestor RelationsorStephen Littlejohn, 314-654-6595Vice President CommunicationsPharmaceuticalsorTodd Carpenter, 508-452-4363DirectorInvestor Relations </0>
  , the pharmaceuticals business of Covidien (NYSE: COV), today joined The Partnership at Drugfree.org in launching , a multi-year effort to raise awareness and curb the abuse of prescription medicine by teens and young adults. Beginning this week, the campaign aims to prevent half a million teens from abusing such medications over the next five years.
  In sponsoring the Medicine Abuse Project, Mallinckrodt continues to build on its dedication to ensuring patient safety. In 2010, Mallinckrodt launched the . This coalition of patient, provider and community organizations provides tools and resources to support the responsible prescribing, and safe and appropriate use, of prescription pain medications.
  Mallinckrodt, the pharmaceuticals business of Covidien, is a vertically integrated leader in providing products used in diagnostic procedures and in the treatment of pain and related conditions. The company is the largest US supplier, by prescription, of opioid pain medications and a leading manufacturer of active pharmaceutical ingredients. It is also the largest US supplier of the medical isotope technetium-99m and an industry leader in radiopharmaceuticals and contrast media and delivery systems. Sales in 2011 were $2.0 billion. Please visit to learn more about our business.